Food & Drug Administration (FDA)
LATEST
Food & Drug Administration (FDA) | Product Liability
Vaccines: Where are We?
As the U.S. marches on with the two approved COVID-19 vaccines, it seems that the original plan to vaccinate 20 million people by the end of 2020 fell a little short. McNees Wallace & Nurick associate, Langdon Ramsburg, assesses where the situation stands and what comes next.
Read MoreMore Food & Drug Administration (FDA) Articles
Food & Drug Administration (FDA)
Vaccines: Where are We?
As the U.S. marches on with the two approved COVID-19 vaccines, it seems that the original plan to vaccinate 20 million people by the end of 2020 fell a little short. McNees Wallace & Nurick associate, Langdon Ramsburg, assesses where the situation stands and what comes next.
Read MoreCannabis
Navigating the Cannabis Industry Gray Zone
Legal advice surrounding the regulatory status of cannabis and hemp-based products is a moving target, but Howard Sklamberg keeps his clients apace.
Read More
Nathan Brown and Howard Sklamberg bring their experience at the Food and Drug Administration to bear when counseling Akin Gump clients on pre- and post-market compliance issues and more.
Read More